Evidence map›Paper›PMID 26884359›Full record

ArticleBreast cancer research : BCR2016

Genetic predisposition to ductal carcinoma in situ of the breast.

Christos Petridis, Mark N Brook, Vandna Shah, Kelly Kohut, Patricia Gorman, Michele Caneppele, Dina Levi, Efterpi Papouli, Nick Orr, Angela Cox and 85 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
7.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  4. Article
  5. Article
  6. Cancers · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Insights into the transition of ductal carcinomaCancer biology & medicine · 2022
    Article
  14. Article
  15. Article
  16. Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort.Genetics in medicine : official journal of the American College of Medical Genetics · 2020
    Article
  17. Article
  18. Article
  19. In Vitro Models for Studying Invasive Transitions of Ductal Carcinoma In Situ.Journal of mammary gland biology and neoplasia · 2019
    Review
  20. The Variant at TGFBRAP1 but Not TGFBR2 Is Associated with Antituberculosis Drug-Induced Liver Injury.Evidence-based complementary and alternative medicine : eCAM · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

95 authors at 20 institutions in 16 countries.

Christos PetridisResearch Oncology, Guy's Hospital, King's College London, London, UK. christos.petridis@kcl.ac.uk.
Mark N BrookDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK. Mark.Brook@icr.ac.uk.
Vandna ShahResearch Oncology, Guy's Hospital, King's College London, London, UK. vandna.shah@kcl.ac.uk.
Kelly KohutCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. kohut.kelly@gmail.com.
Patricia GormanCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. patricia.carlyle@me.com.
Michele CaneppeleCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. michele.caneppele@novartis.com.
Dina LeviResearch Oncology, Guy's Hospital, King's College London, London, UK. dinalevi@gmail.com.
Efterpi PapouliBiomedical Research Centre, King's College London, Guy's Hospital, London, UK. efterpi@cegx.co.uk.
Nick OrrThe Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. Nicholas.Orr@icr.ac.uk.
Angela CoxSheffield Cancer Research, Department of Oncology, University of Sheffield, Sheffield, UK. a.cox@shef.ac.uk.
Simon S CrossAcademic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, UK. s.s.cross@sheffield.ac.uk.
Isabel Dos-Santos-SilvaDepartment of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. isabel.silva@lshtm.ac.uk.
Julian PetoDepartment of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. Julian.Peto@lshtm.ac.uk.
Anthony SwerdlowDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK. Anthony.Swerdlow@icr.ac.uk.
Minouk J SchoemakerDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK. minouk.schoemaker@icr.ac.uk.
Manjeet K BollaCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. mkh39@medschl.cam.ac.uk.
Qin WangCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. qw232@medschl.cam.ac.uk.
Joe DennisCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. jgd29@cam.ac.uk.
Kyriaki MichailidouCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. km533@medschl.cam.ac.uk.
Javier BenitezHuman Cancer Genetics Program, Spanish National Cancer Research Centre, Madrid, Spain. jbenitez@cnio.es.
Anna González-NeiraHuman Cancer Genetics Program, Spanish National Cancer Research Centre, Madrid, Spain. agonzalez@cnio.es.
Daniel C TessierCentre d'innovation Génome Québec et Université McGill, Montréal, Canada. dtessier@genomequebec.com.
Daniel VincentCentre d'innovation Génome Québec et Université McGill, Montréal, Canada. daniel.vincent@mail.mcgill.ca.
Jingmei LiDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. jingmei@gmail.com.
Jonine FigueroaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. figueroaj@mail.nih.gov.
Vessela KristensenDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. v.n.kristensen@medisin.uio.no.
Anne-Lise Borresen-DaleDepartment of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway. a.l.borresen-dale@medisin.uio.no.
Penny SoucyGenomics Center, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec City, Canada. penny.soucy@crchudequebec.ulaval.ca.
Jacques SimardGenomics Center, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec City, Canada. jacques.simard@crchul.ulaval.ca.
Roger L MilneCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia. Roger.Milne@cancervic.org.au.
Graham G GilesCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia. Graham.Giles@cancervic.org.au.
Sara MargolinDepartment of Oncology - Pathology, Karolinska Institutet, Stockholm, Sweden. Sara.Margolin@karolinska.se.
Annika LindblomDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. Annika.Lindblom@ki.se.
Thomas BrüningInstitute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum, Bochum, Germany. bruening@ipa-dguv.de.
Hiltrud BrauchDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany. hiltrud.brauch@ikp-stuttgart.de.
Melissa C SoutheyDepartment of Pathology, The University of Melbourne, Melbourne, Australia. msouthey@unimelb.edu.au.
John L HopperCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global health, The University of Melbourne, Melbourne, VIC, Australia. j.hopper@unimelb.edu.au.
Thilo DörkGynaecology Research Unit, Hannover Medical School, Hannover, Germany. doerk.thilo@mh-hannover.de.
Natalia V BogdanovaDepartment of Radiation Oncology, Hannover Medical School, Hannover, Germany. bogdanova.natalia@mh-hannover.de.
Maria KabischMolecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.kabisch@dkfz.de.
Ute HamannMolecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. u.hamann@dkfz-heidelberg.de.
Rita K SchmutzlerCenter for Familial Breast and Ovarian Cancer, Medical Faculty, University of Cologne and University Hospital Cologne, Cologne, Germany. rita.schmutzler@uk-koeln.de.
Alfons MeindlDivision of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany. alfons.meindl@lrz.tu-muenchen.de.
Hermann BrennerGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. h.brenner@dkfz.de.
Volker ArndtDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. v.arndt@dkfz.de.
Robert WinqvistLaboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland. robert.winqvist@oulu.fi.
Katri PylkäsLaboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, University of Oulu, Oulu, Finland. katri.pylkas@oulu.fi.
Peter A FaschingDepartment of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. peter.fasching@uk-erlangen.de.
Matthias W BeckmannDepartment of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany. Fk-direktion@uk-erlangen.de.
Jan LubinskiDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. lubinski@pum.edu.pl.
Anna JakubowskaDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. aniaj@pum.edu.pl.
Anna Marie MulliganDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada. AnnaMarie.Mulligan@uhn.ca.
Irene L AndrulisLunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada. andrulis@lunenfeld.ca.
Rob A E M TollenaarDepartment of Surgery, Leiden University Medical Center, Leiden, The Netherlands. r.a.e.m.tollenaar@lumc.nl.
Peter DevileeDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands. p.devilee@lumc.nl.
Loic Le MarchandUniversity of Hawaii Cancer Center, Honolulu, HI, USA. loic@crch.hawaii.edu.
Christopher A HaimanDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Christopher.Haiman@med.usc.edu.
Arto MannermaaImaging Center, Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland. arto.mannermaa@uef.fi.
Veli-Matti KosmaImaging Center, Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland. veli-matti.kosma@uef.fi.
Paolo RadiceUnit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto Nazionale dei Tumori (INT), Milan, Italy. paolo.radice@istitutotumori.mi.it.
Paolo PeterlongoIFOM, Fondazione Istituto FIRC (Italian Foundation of Cancer Research) di Oncologia Molecolare, Milan, Italy. paolo.peterlongo@ifom.eu.
Frederik MarmeNational Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany. frederikmarme@gmail.com.
Barbara BurwinkelDepartment of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany. Barbara.Burwinkel@med.uni-heidelberg.de.
Carolien H M van DeurzenDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands. c.h.m.vandeurzen@erasmusmc.nl.
Antoinette HollestelleDepartment of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. a.hollestelle@erasmusmc.nl.
Nicola MillerSchool of Medicine, National University of Ireland, Galway, Ireland. nicola.miller@nuigalway.ie.
Michael J KerinSchool of Medicine, National University of Ireland, Galway, Ireland. michael.kerin@nuigalway.ie.
Diether LambrechtsVesalius Research Center, VIB, Leuven, Belgium. Diether.Lambrechts@med.kuleuven.be.
Giuseppe FlorisUniversity Hospital Gashuisberg, Leuven, Belgium. Giuseppe.Floris@uzleuven.be.
Jelle WesselingNetherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands. j.wesseling@nki.nl.
Henrik FlygerDepartment of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark. henrik.flyger@regionh.dk.
Stig E BojesenCopenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark. stig.egil.bojesen@regionh.dk.
Song YaoDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA. song.yao@roswellpark.org.
Christine B AmbrosoneRoswell Park Cancer Institute, Buffalo, NY, USA. Christine.ambrosone@roswellpark.org.
Georgia Chenevix-TrenchDepartment of Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia. Georgia.Trench@qimrberghofer.edu.au.
Thérèse TruongEnvironmental Epidemiology of Cancer, Center for Research in Epidemiology and Population Health, INSERM, Villejuif, France. therese.truong@inserm.fr.
Pascal GuénelEnvironmental Epidemiology of Cancer, Center for Research in Epidemiology and Population Health, INSERM, Villejuif, France. pascal.guenel@inserm.fr.
Anja RudolphDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. a.rudolph@dkfz.de.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. j.chang-claude@dkfz-heidelberg.de.
Heli NevanlinnaDepartment of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. Heli.Nevanlinna@hus.fi.
Carl BlomqvistDepartment of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. carl.blomqvist@helsinki.fi.
Kamila CzeneDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. kamila.czene@ki.se.
Judith S BrandDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. judith.brand@ki.se.
Janet E OlsonDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. olsonj@mayo.edu.
Fergus J CouchDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. couch.fergus@mayo.edu.
Alison M DunningCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK. amd24@medschl.cam.ac.uk.
Per HallDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Per.Hall@ki.se.
Douglas F EastonCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. dfe20@medschl.cam.ac.uk.
Paul D P PharoahCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. pp10001@medschl.cam.ac.uk.
Sarah E PinderResearch Oncology, Guy's Hospital, King's College London, London, UK. sarah.pinder@kcl.ac.uk.
Marjanka K SchmidtNetherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands. mk.schmidt@nki.nl.
Ian TomlinsonWellcome Trust Centre for Human Genetics and Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford, UK. iant@well.ox.ac.uk.
Rebecca RoylanceCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. r.roylance@qmul.ac.uk.
Montserrat García-ClosasDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK. montserrat.garcia-closas@nih.gov.
Elinor J SawyerResearch Oncology, Guy's Hospital, King's College London, London, UK. elinor.sawyer@kcl.ac.uk.
German Cancer Research Center · DEUniversity of Cambridge · GBGuy's Hospital · GBKarolinska Institutet · SEInstitute of Cancer Research · GBQueen Mary University of London · GBThe University of Melbourne · AUCentre hospitalier universitaire de Québec · CAInserm · FRLeiden University Medical Center · NLLondon School of Hygiene & Tropical Medicine · GBMedizinische Hochschule Hannover · DENational University of Ireland · IENordLab · FIOslo University Hospital · NOPomeranian Medical University · PLRoswell Park Comprehensive Cancer Center · USSpanish National Cancer Research Centre · ESThe Netherlands Cancer Institute · NLUniversity of Eastern Finland · FI

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
Understanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4M
GENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSR01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2001 to 2005
$23.2M
Multiethnic Cohort Study of Diet and CancerR37CA054281 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 2003 to 2012
$23.2M
Breast Cancer Family Registry CohortUM1CA164920 · NCI · CANCER PREVENTION INSTIT OF CALIFORNIA · PI ANDRULIS, IRENE, BUYS, SAUNDRA S · 2012 to 2017
$12.7M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098758 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2003 to 2010
$11.0M
Epidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6M
Epidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4M
Ovarian cancer GWAS discovery, expansion and replication (N2 - Project #1)U19CA148112 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2010 to 2014
$10.2M
A genome-wide association study for breast cancer in BRCA1 mutation carriersR01CA128978 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH · 2008 to 2012
$4.8M
MULTIETHNIC/MINORITY COHORT STUDY OF DIET AND CANCERR01CA054281 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 1993 to 2002
$4.5M
Cancer Research UK 10119Cancer Research UK 10124Cancer Research UK 16561Cancer Research UK 16563Cancer Research UK 16565Cancer Research UK C12292/A11174Cancer Research UK C1281/A12014Cancer Research UK C1287/A10118Cancer Research UK C1287/A 10710Cancer Research UK C1287/A12014Cancer Research UK C490/A10124Cancer Research UK C5047/A10692Cancer Research UK C5047/A15007Cancer Research UK C5047/A8384Cancer Research UK C8197/A16565CIHRMedical Research Council MC_PC_14105NCI NIH HHS CA098758NCI NIH HHS CA116167NCI NIH HHS CA116201NCI NIH HHS CA128978NCI NIH HHS CA132839NCI NIH HHS CA176785NCI NIH HHS CA54281NCI NIH HHS CA63464NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA016056-32NCI NIH HHS P50 CA116201NCI NIH HHS R01 CA054281NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA116167NCI NIH HHS R01 CA128978NCI NIH HHS R01 CA132839NCI NIH HHS R01 CA176785NCI NIH HHS R37 CA054281NCI NIH HHS U01 CA063464NCI NIH HHS U01 CA098758NCI NIH HHS U01 CA116167NCI NIH HHS U01 CA164973NCI NIH HHS U19 CA148065NCI NIH HHS U19 CA148112NCI NIH HHS U19 CA148537NCI NIH HHS UM1 CA164920Wellcome TrustWellcome Trust 090532/Z/09/Z
6 · The paper itself

Abstract

backgroundDuctal carcinoma in situ (DCIS) is a non-invasive form of breast cancer. It is often associated with invasive ductal carcinoma (IDC), and is considered to be a non-obligate precursor of IDC. It is not clear to what extent these two forms of cancer share low-risk susceptibility loci, or whether there are differences in the strength of association for shared loci.

methodsTo identify genetic polymorphisms that predispose to DCIS, we pooled data from 38 studies comprising 5,067 cases of DCIS, 24,584 cases of IDC and 37,467 controls, all genotyped using the iCOGS chip.

resultsMost (67 %) of the 76 known breast cancer predisposition loci showed an association with DCIS in the same direction as previously reported for invasive breast cancer. Case-only analysis showed no evidence for differences between associations for IDC and DCIS after considering multiple testing. Analysis by estrogen receptor (ER) status confirmed that loci associated with ER positive IDC were also associated with ER positive DCIS. Analysis of DCIS by grade suggested that two independent SNPs at 11q13.3 near CCND1 were specific to low/intermediate grade DCIS (rs75915166, rs554219). These associations with grade remained after adjusting for ER status and were also found in IDC. We found no novel DCIS-specific loci at a genome wide significance level of P < 5.0x10(-8).

conclusionIn conclusion, this study provides the strongest evidence to date of a shared genetic susceptibility for IDC and DCIS. Studies with larger numbers of DCIS are needed to determine if IDC or DCIS specific loci exist.

Indexed as

Genetic Association StudiesAdultAgedBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCyclin D1Erb-b2 Receptor Tyrosine KinasesFemaleGenotypeHumansKi-67 AntigenMiddle AgedNeoplasm ProteinsPolymorphism, Single NucleotideReceptors, EstrogenCCND1 protein, humanCyclin D1Erb-b2 Receptor Tyrosine KinasesKi-67 AntigenNeoplasm ProteinsReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID26884359
PMCPMC4756509
OpenAlexW2287794423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.